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BRIAN E. lASKI, MD, WILLIAM H. BARRY, MD, FACC
Boston, Massachusetts
To evaluate the short-term hemodynamic and neuroen-
docrine effects of nifedipine in heart failure, it was com-
pared with nitroprusside, a balanced vasodilator without
known inotropic effect, in equihypotensive doses during
right and left heart catheterization in nine patients with
heart failure. Mean arterial pressure decreased from 89
± 12 to 76 ± 14 mm Hg with nitroprusside, and from
90 ± 12 to 75 ± 13 mm Hg with sublingual nifedipine.
Right atrial, pulmonary artery, pulmonary capillary
wedge and left ventricular end-diastolic pressures de-
creased significantly with nitroprusside, but not with
nifedipine. Cardiac index and stroke volume index in-
creased to a similar extent with both drugs; in contrast,
stroke work index increased significantly with nitro-
prusside, but not with nifedipine. Peak rate of left ven-
tricular pressure development (dP/dt) (measured with a
micromanometer-tipped catheter in seven patients) was
Within the past decade, vasodilators have assumed a prom-
inent role in the management of heart failure (I). A variety
of pharmacologic agents are available for this purpose. Re-
cently, it has been proposed that the calcium channel block-
ing agent nifedipine might also be useful in the treatment
of heart failure because of its potent peripheral vascular
effects (2-8). Several important aspects of the action of
nifedipine in patients with severe heart failure have not,
however, been adequately addressed. In particular, the rel-
ative effects of nifedipine on afterload, preload and con-
tractility remain controversial. Some investigators (2-4,
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unchanged with nitroprusside, but decreased signifi-
cantly with nifedipine (747 ± 292 to 639 ± 238 mm
Hg/s; p < 0.002). There was no change in heart rate
with either medication. Plasma norepinephrine and epi-
nephrine concentrations were not altered significantly
by either drug. Plasma renin activity was not changed
by nitroprusside infusion, but was increased after the
administration of nifedipine.
Thus, in contrast to the balanced vasodilator action
of nitroprusside, the effectof nifedipine is predominantly
on the arterial circulation. In these patients with heart
failure, reflex sympathetic stimulation did not occur in
response to a decrease in systemic arterial pressure by
either vasodilator. A negative inotropic effect occurred
after the administration of nifedipine, but not nitro-
prusside.
(J Am Coil CardioI1985;5:731-7)
6,7,9,10) have reported a significant decrease in left heart
filling pressure after short-term administration of nifedipine,
whereas others (5,8,11-13) have found little change in this
index of preload. Moreover, the negative inotropic effect
of nifedipine that can be demonstrated in vitro (14) and after
intracoronary administration in human subjects (15, 16) might
be detrimental if present after systemic administration of
nifedipine to patients with heart failure. In patients without
heart failure, systemic administration of nifedipine may
produce a positive inotropic effect caused by reflex sym-
pathetic activity consequent to the hypotensive effect of
vasodilation. No direct evidence is currently available re-
garding the effect of nifedipine on myocardial inotropic state
in patients with a severely depressed baseline left ventricular
function, although indirect hemodynamic evidence suggests
that it may exert a negative inotropic effect (12,13). Finally,
the overall hemodynamic and clinical actions of nifedipine
in patients with heart failure might be importantly modified
by neuroendocrine responses to calcium channel blockade
(17).
To assess more directly the inotropic action of nifedipine,
we studied its hemodynamic effects during left heart cath-
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eterization with a micromanometer-tipped catheter, which
allowed us to measure the peak rate of left ventricular pres-
sure development (dP/dt). This variable, like many indexes
of contractility, is influenced by loading conditions (18).
To take these into account, we compared the effects of
nifedipine with those of nitroprusside, a vasodilator without
known positive or negative inotropic effect (19), using
equihypotensive doses of the two drugs.
Methods
Patients. Nine patients (seven men and two women, 36
to 81 years of age) in New York Heart Association func-
tional class III or IV referred for diagnostic cardiac cathe-
terization formed the study group. All had dyspnea or fa-
tigue, or both, despite therapy with digoxin and diuretic
drugs. Six patients had been treated with vasodilator drugs.
All had an elevated pulmonary capillary wedge pressure and
a low left ventricular ejection fraction (0.07 to 0.42). Seven
patients had coronary artery disease, one had doxorubicin
cardiotoxicity and one had alcoholic cardiomyopathy; none
had primary valvular heart disease. Patient 9 had a ventric-
ular paced rhythm; the remaining eight patients were in sinus
rhythm. The study protocol was approved by the Committee
for the Protection of Human Subjects From Research Risks
of the Brigham and Women's Hospital on December 9,
1981. Informed written consent was obtained from all patients.
Data collection. Vasodilator drugs were withheld for 48
hours before the study. Digoxin and diuretic drugs were
withheld on the morning of the study. Antiarrhythmic med-
ications were administered as scheduled. Studies were per-
formed under mild sedation (diazepam,S to 10 mg orally
and diphenhydramine, 25 to 50 mg orally) and local anes-
thesia with I% lidocaine. In those patients in whom contrast
studies were performed, at least 20 minutes were allowed
to elapse after angiography before initiation of the study
protocol.
Measurements included: I) heart rate, 2) systemic arte-
rial, right atrial, pulmonary artery and pulmonary capillary
wedge pressures, 3) left ventricular pressure recorded with
a micromanometer-tipped catheter (Mikro-Tip, Millar In-
struments), calibrated externally against a mercury reference
and matched simultaneously against luminal pressure, 4)
first time derivative of left ventricular pressure (dP/dt, by
electronic differentiation), 5) cardiac output (by the Fick
technique), 6) plasma norepinephrine and epinephrine con-
centrations (by radioenzymatic assay [20]), and 7) plasma
renin activity (by radioimmunoassay of angiotensin I [21]).
Normal values (± standard deviation) in our laboratory are:
norepinephrine, 213 ± 30 pg/rnl; epinephrine, 28 ± 8
pg/ml; plasma renin activity, 5.2 ± 1.3 ng/ml per h (on a
low sodium diet).
Drug administration. Nitroprusside (sodium nitroprus-
side, Elkins-Sinn) infusion was begun at 15 /Lg/min, and
the dose was increased at 10 minute intervals until mean
arterial pressure had decreased by approximately 10 mm
Hg. Hemodynamic, catecholamine and renin measurements
were made, the nitroprusside infusion rate was further in-
creased to achieve an approximately 20 mm Hg decrease in
mean arterial pressure and measurements were repeated.
These levels of mean arterial pressure decrease were chosen
to approximate the likely decrease in pressure after nifed-
ipine administration, based on prior experience with this
drug. Determination of oxygen consumption was repeated
at the second infusion rate. After discontinuation of nitro-
prusside, sufficient time, usually at least IS minutes, was
allowed for return of heart rate, systemic arterial pressure,
filling pressures and cardiac output to baseline conditions;
control measurements were then repeated.
Nifedipine (Procardia, Pfizer Pharmaceuticals Division)
was then administered; all patients received 20 mg sublin-
gually, except for Patients 4 and 7 who received 10 mg
because of concern regarding excessive blood pressure de-
crease in response to the drug, and Patient 2 who received
30 mg because of lack of response to the lower dose. Mea-
surements, including oxygen consumption, were made 30
minutes later. The order of nitroprusside and nifedipine
administration was not randomized because of the much
longer duration of action of nifedipine.
Data analysis. Mean pressures were determined by elec-
tronic integration. There were no significantdifferencesamong
oxygen consumption measurements in the baseline state, at
peak nitroprusside infusion rate and after nifedipine admin-
istration; therefore, the mean of these three values was used
for subsequent calculations. Fick cardiac output, cardiac
index, systemic and pulmonary vascular resistance and stroke
volume index were calculated according to standard for-
mulas (22). Stroke work index (g/m per rrr') was calculated
as 0.0136 X (stroke volume index [rnl/rrr'[) x (mean sys-
temic arterial pressure - left ventricular end diastolic pres-
sure [mm Hg]).
The nitroprusside infusion rate that yielded mean arterial
pressure closer to that after nifedipine administration was
chosen for analysis of the comparative hemodynamic and
neuroendocrine effects of the two drugs.
Statistical analysis. All results are expressed as mean
± standard deviation, except as indicated. For each mea-
surement, overall comparisons among the initial control,
nitroprusside, second control and nifedipine periods were
made by two-way analysis of variance; overall differences
were considered significant if p < 0.05. For those variables
for which overall differences were significant, comparisons
between pairs of treatment periods were made using a mod-
ified t test and Bonferroni' s method for multiple simulta-
neous comparisons (23). Differences between initial and
second control, control and nitroprusside, second control
and nifedipine and nitroprusside and nifedipine periods were
considered significant if p < 0.05/4 = 0.0125.
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Figure I. Effects of nitroprusside (NTP) and nifedipine (NIF) on
mean systemic arterial pressure. mean right (RT) atrial pressure,
left ventricular end-diastolic pressure and cardiac index. Mean
values and standard deviations are shown. By study design, the
effects of the two drugs on mean arterial pressure were similar
(A). Nitroprusside, butnotnifedipine, lowered right atrial pressure
(8 ) and left ventricular end-diastolic pressure (C) . The two drugs
augmented cardiac index to a similar extent (D ). C 1 = initial



















dynes.s-em - 5 , p < 0.002) but not for nitroprusside (194 ±
122 to 139 ± 54 dynes-scm t ') .
Stroke volume index increased by similar amounts with
nitroprusside (29 ± 6 to 37 ± 5 rnl/m", p < 0.001) and
nifedipine (30 ± 8 to 39 ± 7 ml/m", p < 0.(01). Stroke
work index increased significantly with nitroprusside (24 ±
6 to 31 ± 9 g/m per m", p < 0.(02), but not with nifedipine
(23 ± 6 to 27 ± 8 glm per rrr'). Figure 2 depicts the relative
effects of nitroprusside and nifedipine on left ventricular
end-diastolic pressure , stroke volume index and stroke work
index. Stroke volume index was similar with nitroprusside
and nifedipine, but left ventricular end-diastolic pressure
was higher with nifedipine than with nitroprusside. Stroke
work index was higher with nitroprusside than with nifed-
ipine because left ventricular end-diastolic pressure was lower
with nitroprusside in the presence of a similar mean arterial
pressure and stroke volume index.
Left ventricular dPldt was measured in seven of the nine
patients . Nitroprusside caused a decreased arterial pressure,
but did not alter peak positive left ventricular dP/dt (787 ±
327 to 772 ± 303 mm Hg/s) (Fig. 3). In contrast, nifedipine
decreased systemic arterial pressure to a similar extent, but
C 40 a
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Results
Baseline hemodynamic and biochemical data. Baseline
heart rate was 85 ± 13 beats/min in the first control period
and 82 ± 12 beats/min in the second control period. Mean
systemic arterial pressure was 89 ± 12 and 90 ± 12 mm
Hg, respectively , in the two control periods. In the first and
second control periods, respectively, right atrial (9 ± 4 and
8 ± 4 mm Hg), pulmonary capillary wedge (27 ± 8 and
23 ± 7 mm Hg) and left ventricular end-diastolic (29 ± 7
and 27 ± 5 mm Hg) pressures were elevated and cardiac
index (2.4 ± 0.3 and 2.4 ± 0.4 liters/min per m2) was
depressed . Systemic vascular resistance (1,493 ± 258 and
1,515 ± 267 dynes-s-cm - 5) was at the upper limit of the
normal range, and pulmonary vascular resistance (194 ±
122 and 219 ± 134 dynes-s-cm t ' ) was mildly increased.
Baseline plasma norepinephrine (391 ± 178 and 344 ±
149 pg/rnl) and epinephrine (72 ± 55 and 76 ± 60 pg/ml)
concentrations were elevated . Plasma renin activity varied
over a wide range (1.0 to 21, mean 5.0 ± 6. I ng/ml per
h for the first control period and 0.8 to 19, mean 4.9 ±
5.5 ng/ml per h for the second). There were no significant
differences between values for the initial and second control
periods for any of the variables.
Comparative hemodynamic responses to nitroprus-
side and nifedipine. The mean nitroprusside infusion rate
was 63 ± 44 p.g/min , and the mean nifedipine dose was
19 ± 6 mg. By study design, the decrease in mean arterial
pressure was similar with the two medications, from 89 ±
12 to 76 ± 14 mm Hg with nitroprusside (p < 0.001 ) and
from 90 ± 12 to 75 ± 13 mm Hg with nifedipine (p <
0.001) (Fig. IA). Despite this decrease in systemic arterial
pressure, there was no change in heart rate with either med-
ication (81 ± 12 beats/min with nitroprusside, 82 ± 10
beats/min with nifedipine). Right atrial pressure decreased
significantly with nitroprusside from 9 ± 4 to 5 ± 3 mm
Hg (p < 0.00 I), but was unchanged with nifedipine (8 ±
4 to 8 ± 4 mm Hg) (Fig. IB). Pulmonary capillary wedge
pressure decreased from 27 ± 8 to 13 ± 7 mm Hg with
nitroprusside (p < 0.00 I), but was not altered by nifedipine
(23 ± 7 to 24 ± 7 mm Hg). Left ventricular end-diastolic
pressure decreased with nitroprusside from 29 ± 7 to 15
± 5 mm Hg (p < 0.00 I), but not with nifedipine (27 ±
5 to 26 ± 4 mm Hg) (Fig. IC). Cardiac index increased
to a similar extent with the two drugs, from 2.4 ± 0.4 to
3.0 ± 0.6 liters/min per m2 with nitroprusside (p < 0.002)
and from 2.4 ± 0.4 to 3.2 ± 0.7 liters/min per m2 with
nifedipine (p < 0.00 I) (Fig. 10). Systemic vascular re-
sistance decreased significantly with both nitroprusside and
nifedipine, and was similar with the two drugs (1,084 ±
185dynes-scm - 5 with nitroprusside, 936 ± 198dynes-scm - 5
with nifedipine). Pulmonary vascular resistance decreased
with both medications; the difference achieved statistical
significance for nifedipine (219 ± 134 to 121 ± 48
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Figure 2. Relative effects of nitroprus-
side (NTP) and nifedipine (NIF) on left
ventricularend-diastolic pressure, stroke
volume indexandstroke workindex. Mean
values and standard errors of the mean
are shown.Strokevolumewasaugmented
by a similar amount with both drugs, but
only nitroprusside simultaneously de-
creasedleft ventricularend-diastolic pres-
sure. Stroke work index was increased
with nitroprusside, but not with nifedi-
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tion of nifedipine (4.9 ± 5.5 to 9.3 ± 11.8 ng/ml per h,
p < 0.01).
Discussion
Negative inotropic effect of nifedipine. To our knowl-
edge, this is the first study directly demonstrating a negative
inotropic effect after sublingual administration of nifedipine
in human subjects. Verapamil, another calcium channel
blocking agent, may cause cardiac decompensation in pa-
tients with preexisting severe left ventricular dysfunction
(24), presumably by a direct negative inotropic action. Like
verapamil, nifedipine exerts a negative inotropic effect in
vitro (14). Although the intracoronary administration of ni-
fedipine in patients without heart failure results in depressed
regional left ventricular systolic function (15,16), the intra-
venous injection of nifedipine in similar patients improves
overall left ventricular pump function, possibly because of
a reduction in afterload and a reflex increase in sympathetic
stimulation (15).
In our study, peak positive left ventricular dP/dt de-
creased after nifedipine administration. This index of con-
tractility is partially afterload-dependent; higher levels of
afterload are associated with higher values of dP/dt (18).
We therefore assessed peak positive left ventricular dP/dt
at similar systemic arterial pressure during nitroprusside
infusion, and found no depression of this index. In addition,
dP/dt is in part preload-dependent, increasing after volume
loading (18). Left ventricular end-diastolic pressure, how-
ever, was higher after nifedipine than after nitroprusside;
this higher preload would be expected to increase, not de-
crease, peak positive left ventricular dP/dt. The absence of
significant changes in heart rate or catecholamine levels
during nitroprusside infusion suggests that reflex positive
inotropic stimulation did not occur. We therefore conclude
that nifedipine exerted a direct negative inotropic effect in
these patients.
We also assessed left ventricular contractile function by













caused a decrease in peak positive left ventricular dP/dt from
747 ± 2~, to 639 ± 238 mm Hg/s (p < 0.002) (Fig. 3).
Compltrative biochemical responses to nitroprusside
and nifedieine! Plasma norepinephrine and epinephrine
concentrationswere not altered significantly with either ni-
troprusside (383 ± 122 and 74 ± 51 pg/rnl, respectively)
or nifedipine (465 ± 173 and 161 ± 164 pg/ml, respec-
tively), consistent with the lack of reflex effect of either
drug on heart rate. Plasma renin activity was not changed
with nitroprusside infusion (5.1 ± 5.7 ng/ml per h), but
was significantly elevated 30 minutes after the administra-
Figure 3. Changes in peak positive left ventricular dP/dt
(LV+dP/dt) on nitroprusside (NTP) and nifedipine (NIF). Mean
values and standard deviations are shown. Nifedipine, but not
nitroprusside, decreased peak positive dP/dt. Other abbreviations
as in Figure I.
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pressure and stroke volume index. Equihypotensive doses
of nitroprusside and nifedipine augmented stroke volume
index by similar amounts, but with nifedipine this was as-
sociated with a substantially higher left ventricular filling
pressure. These findings are in agreement with those of
Elkayam et al. (13) and corroborate our conclusion that
nifedipine has a negative inotropic action.
Role of blunted reflex sympathetic response . It is likely
that we were able to demonstrate the negative inotropic
effect of nifedipine in this study because these patients with
severe heart failure had a blunted reflex sympathetic re-
sponse to the hypotensive effect of vasodilation. Despite
the decrease in mean arterial pressure, there was no change
in heart rate or plasma catecholamine levels with either
nitroprusside or nifedipine in our patients with heart failure.
In a study of II patients with heart failure, Brodie et al.
(25) found that the administration of nitroprusside did not
alter heart rate despite a dramatic decrease in systemic ar-
terial pressure. Olivari et al. (26) observed that nitroprusside
administration resulted in increases in heart rate and plasma
norepinephrine concentration in normal subjects. but not in
patients with heart failure. Similarly, Porteret al. (27) found
that both nitroprusside and diltiazem caused an increase in
heart rate in dogs before, but not 2 to 4 weeks after. creation
of an arteriovenous fistula. Nifedipine often causes tachy-
cardia in patients without heart failure (28), but most in-
vestigators (2-4,6-8 ,12,13) have found no change in heart
rate after its administration in patients with heart failure.
The lack of a significant effect of nifedipine on either heart
rate or catecholamine levels in our study is in agreement
with the findings of Prida et al. (8) and reflects the generally
diminished sympathetic responsiveness to hypotensive stim-
uli in patients with heart failure (29).
In normal subjects or in patients with coronary artery
disease without heart failure. the direct negative inotropic
effect of nifedipine would likely be offset by the positive
inotropic effect of reflex sympathetic stimulation. Nakaya
et al. (30) showed that the intravenous administration of
nifedipine in conscious dogs caused marked tachycardia and
an elevation in peak dP/dt; after premedication with pro-
pranolol, however, the heart rate response to nifedipine was
blunted and peak dP/dt decreased slightly. Porter et al. (27)
observed that the administrationof diltiazem indogs resulted
in an increase in heart rate and no change in dP/dt; after a
long-term volume overload state was induced, diltiazem did
not increase heart rate and dP/dt decreased. These results
suggest that attenuation of reflexsympathetic inotropicstim-
ulation, (for example, by pharmacologic beta-adrenergic
blocking agents or the effects of long-term heart failure)
may unmask the negative inotropic effect of those calcium
channel blocking agents, such as nifedipine and diltiazem.
that are also potent vasodilators.
Vasodilator effects of nifedipine. Although the vaso-
dilator effect of nifedipine on the arterial circulation and.
hence, its effect on afterload are undisputed, the influence
of this calcium channel blocking agent on left ventricular
filling pressure has been controversial. Several studies
(2-4 ,6.7,9) have demonstrated a significant decrease in left
heart filling pressure after nifedipine administration, whereas
others (5.8 .11-13) have found no signifi cant change in this
variable.
In the present study, we measured left ventricular end-
diastolic pressure directly with a micromanometer-tipped
catheter. Nifedipine had no significant effect on left ven-
tricular end-diastolic pressure; for a similar decrease in mean
arterial pressure and systemic vascular resistance, nitro-
prusside markedly decreased left ventricular end-diastolic
pressure. This is consistent with the lack of important veno-
dilation in response to nifedipine (10), as corroborated by
the absence of a significant decrease in right atrial pressure
in this and previous (3.5.7,8,11) studies. The decrease in
left heart filling pressure seen in two of the nine patients in
this study and in some of the patients in previous studies
may have resulted from amelioration of mitral regurgitation.
Alternatively, diastolic left ventricular distensibility may
have been improvedby nifedipine, either directly or through
relief of myocardial ischemia (31,32).
Neuroendocrine effects of nifedipine. Plasma renin ac-
tivity was increased by nifedipine, but not by nitroprusside.
The lack of change in renin activity during the hypotensive
stimulus of nitroprusside infusion in patients with heart fail-
ure has been noted by Vrobel and Cohn (33). Prida et al.
(8) recently reported an increase in renin activity after ni-
fedipine administration in patients with heart failure. Im-
portant stimuli for renin secretion include beta-adrenergic
activity and reduction in renal blood flow caused by a de-
crease in systemic arterial pressure or redistribution of blood
away from the kidney. Our data suggest that significant
reflex sympathetic stimulation did not occur after nifedipine
administration. Systemic arterial pressure was lowered by
nifedipine, but a similar decrease in systemic pressure dur-
ing nitroprusside infusion did not increase renin activity. It
is possible that nifedipine had a deleterious effect on renal
blood flow as a result of redistribution of cardiac output to
other vascular beds. An alternative hypothesis is that the
calcium channel blocking action of nifedipine directly stim-
ulated renin release. In this regard, it has been hypothesized
that a decrease in cytoplasmic calcium concentration is the
proximate stimulus to renin release (34). Activation of the
renin-angiotensin-aldosterone system by nifedipine might
result in attenuation of the vasodilator effect of the drug due
to the vasoconstrictor action of angiotensin II and to fluid
retentioncaused by an increase in aldosterone secretion (17).
Limitations of the study. Potential limitations of the
present study need to be considered. In the absence of left
ventricular volume data, we used systemic arterial pressure
as an indicator of left ventricular afterload and left ventric-
ular end-diastolic pressure as a measure of preload. Ideally,
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left ventricular afterload would be represented by systolic
wall stress, although calculation of this variable would be
problematic in the presence of regional wall motion abnor-
malities in those patients with heart failure caused by coro-
nary artery disease. The use of systemic arterial pressure in
place of wall stress ignores left ventricular dimension and
wall stress data; because changes in these factors are ex-
pected to be directionally similar on nitroprusside and ni-
fedipine, however, systematic errors in the comparison of
these two drugs should be minimal. In addition, because
systemic vascular resistance was similar with the two drugs,
use of this variable in place of systemic arterial pressure as
an index of afterload would not affect our conclusions.
The use of left ventricular end-diastolic pressure rather
than end-diastolic volume (which would more directly re-
flect end-diastolic fiber length) as an index of preload is
predicated on the assumption that left ventricular distensi-
bility remained constant throughout the study. It has been
shown, however, that both nitroprusside (25,35) and nifed-
ipine (9) may increase left ventricular distensibility in pa-
tients with heart failure, possibly by unloading the right
ventricle. Because nitroprusside, as shown in this study,
has a greater effect on right ventricular filling pressure than
does nifedipine, the decrease in left ventricular end-diastolic
pressure on nitroprusside may have exaggerated the actual
change in left ventricular preload. This consideration does
not, however, have any bearing on the finding that peak
dP/dt decreased with nifedipine, but not with nitroprusside.
Finally, the effects of long-term therapy with nifedipine
may be different from those of short-term administration of
a single dose. This study has not addressed the effects of
nifedipine on hemodynamics in the upright posture or during
exercise.
Conclusions. A negative inotropic effect of nifedipine
was demonstrated after systemic administration in patients
with heart failure. Nifedipine is a predominantly arterial
vasodilator, with little or no effect on left or right heart
filling pressures. Plasma renin activity is increased by the
short-term administration of nifedipine, possibly by a direct
effect of calcium channel blockade on renin release. In
patients without heart failure, the negative inotropic effect
of nifedipine is masked by the positive inotropic effect of
reflex sympathetic stimulation. In the setting of heart failure,
this reflex response is blunted or absent. In comparison with
nitroprusside, the increase in cardiac output on nifedipine
is similar, but is achieved at a higher left ventricular filling
pressure. The negative inotropic effect of nifedipine may
be detrimental in patients with a baseline depression of left
ventricular systolic function.
Nifedipine (Procardia) was supplied by Pfizer Pharmaceuticals Division.
New York. New York. We gratefully acknowledge the helpful comments
and suggestions of Eugene Braunwald, MD. William Grossman. MD and
loshua Wynne. MD.
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